Long-acting injectable cabotegravir,
does it really help with Reduced sexually acquired HIV-1 infection as pre-exposure prophylaxis in HIV-negative adults at high risk?
research showsLong-acting injectable cabotegravir for PrEP is rated A. In HPTN 083, involving 4,566 cisgender men and transgender women, HIV infection was 66% less frequent than with oral TDF/FTC (HR 0.34, 95% CI 0.18 to 0.62). In HPTN 084, involving 3,224 African women, it was 88% less frequent (HR 0.12, 95% CI 0.05 to 0.31). Two large randomized trials in different sex and geographic populations reproduced a large effect on confirmed incident HIV infection, a hard outcome, and the comparator was already-effective oral PrEP. This is direct, molecule-specific comparative superiority evidence. Injection-site reactions and the risk of integrase-inhibitor resistance during unrecognized acute HIV infection or dosing gaps remain separate safety issues.
ads claimPromotion can make the regimen sound like perfect protection from one injection every two months. The first two injections are one month apart, appointments and HIV testing remain essential, and condoms, sexually transmitted infection care, and a plan for alternative PrEP after discontinuation remain part of comprehensive prevention.
Useful facts when choosing a product
- Apretude is a long-acting cabotegravir intramuscular injection for sexual HIV-1 pre-exposure prophylaxis in HIV-negative adults and adolescents weighing at least 35 kg.
- United States labeling uses a 600-mg gluteal intramuscular injection one month apart for the first two doses and every two months thereafter; an oral lead-in to assess tolerability is optional.
- Testing capable of detecting acute or primary HIV infection is required before initiation and with every injection, and confirmed infection requires prompt transition to a complete HIV treatment regimen.
- Injection-site pain and nodules are common, while hypersensitivity, hepatotoxicity, and depressive disorders have been reported. Drug can remain for 12 months or longer, so alternative PrEP should begin within two months after the last injection when ongoing risk remains.
What the research actually shows
HPTN 083 double-masked 4,566 HIV-negative cisgender men and transgender women to cabotegravir 600-mg intramuscular injections every eight weeks or daily oral TDF/FTC strategies. Incident infections numbered 13 versus 39, HR 0.34, and the trial was unblinded early for efficacy at a prespecified interim analysis. HPTN 084 randomized 3,224 women in sub-Saharan Africa to the same strategies; among 3,209 analyzed participants there were 4 versus 36 infections, HR 0.12. Delayed diagnosis and integrase-inhibitor resistance occurred in some cabotegravir-arm infections, making sensitive HIV testing before every injection essential. WHO recommends cabotegravir LA as an additional PrEP option for people at substantial risk, but the grade rests on the trials rather than the guideline.
Why this is classified as A (92)
HPTN 083 and HPTN 084 reduced confirmed HIV infection versus effective oral PrEP with hazard ratios of 0.34 and 0.12 in different high-risk adult populations. Large randomized double-masked direct comparisons, replication, a hard endpoint, and attribution to the long-acting cabotegravir strategy support A with 92 points. Injection reactions and resistance after delayed diagnosis remain separate safety concerns.
Counterpoint. Daily oral TDF/FTC remains a highly effective option for people able to take it consistently. Choice should also consider access to two-monthly visits, injection preference, cost, renal and bone health, pregnancy plans, and the injection's prolonged pharmacologic tail.
Rejudgment record. New verdict — Large randomized double-masked HPTN 083 and HPTN 084 direct comparisons showed substantially fewer incident HIV-1 infections than effective oral TDF/FTC and replicated the result across different sex and geographic populations, satisfying hard-outcome and molecule-attribution rules
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of sexually acquired HIV-1 infection in HIV-negative adults at high risk | A | Two large randomized trials substantially reduced laboratory-confirmed incident infection. |
| Superior prevention of infection versus daily oral TDF/FTC PrEP | A | Active-control superiority was replicated with HR 0.34 in HPTN 083 and HR 0.12 in HPTN 084. |
| Preventive efficacy in men, transgender women, and cisgender women | A | Large trials in different sex and geographic populations showed consistent direction and magnitude. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Landovitz RJ et al. 2021 HPTN 083 | Phase 3 randomized double-blind double-dummy active-controlled trial | 4,566 | U.S. NIAID and partners | Laboratory-confirmed incident HIV infection | Thirteen infections with cabotegravir versus 39 with TDF/FTC; HR 0.34 (95% CI 0.18 to 0.62). | Pivotal large direct hard-outcome trial |
| Delany-Moretlwe S et al. 2022 HPTN 084 | Phase 3 randomized double-blind double-dummy active-controlled superiority trial | 3,209 | U.S. NIAID and partners | Laboratory-confirmed incident HIV infection | Four infections with cabotegravir versus 36 with TDF/FTC; HR 0.12 (95% CI 0.05 to 0.31). | Large pivotal replication in a different sex and geographic population |
| World Health Organization 2022 guideline | GRADE-based international clinical and public-health guideline | 084 | World Health Organization | HIV infection, adverse events, resistance, and feasibility | Recommended that CAB-LA may be offered as an additional PrEP option to people at substantial HIV risk. | External synthesis and implementation context |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Long-acting injectable cabotegravir x prevention of sexually acquired HIV-1 infection — Evidence Grade A·92. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/cabotegravir-la-prep-sexual-hiv-1-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.